At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
Lasmiditan +3 moredrug
Likely dose
Lasmiditan 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Lasmiditan, Placebo, and 1 other intervention for Healthy. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days for each participant, not including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
CollaboratorsCoLucid Pharmaceuticals
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
Primary CompletionDec 2011
First PostedMar 2018
TodayJul 2026
First PostedMar 14, 2018
Enrollment StartSep 16, 2011
Primary CompletionDec 20, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.3 years ago
Interventions
Lasmiditandrug
100 mg administered orally (PO)
Lasmiditandrug
400 mg administered PO
Placebodrug
Placebo administered for lasmiditan or moxifloxacin
Moxifloxacindrug
400 mg moxifloxacin administered PO